F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With Acute Myeloid Leucemia(AML) — AML F18-FLT  

Acute Myeloid Leucemia Clinical Trial

Official title: F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With AML

Status Not yet recruiting

Clinical Trial Summary

PET/CT is reliable tool in evaluation of treatment response in number cancers. F18-FLT is a precursor of DNA with high uptake in the bone marrow as a part of normal biodistribution. Highly increased uptake of this radiopharmaceutical was shown in a number of hematologic disease either in bone marrow or extramedullary.

F18-FLT PET/CT can provide a tool for whole body assessment of activity in bone marrow as well as early estimation of treatment efficacy or lack of it. In addition, this noninvasive study can replace bone marrow biopsy and predict response vs. non response to therapy.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Acute Myeloid Leucemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

• NCT number: NCT01592266
• Study type: Observational
• Source: Hadassah Medical Organization
• Contact: Marina Orevi, MD
• Email: marinaor@hadassah.org.il
• Status: Not yet recruiting
• Phase: N/A
• Start date: October 2012